Publication | Open Access

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Randomized Phase 2MedicinePharmacologyPathologyImmune Checkpoint InhibitorFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology